In this audio interview conducted on June 3, 2020, the editors discuss two new studies: one comparing test swabs collected by health care workers with swabs collected by the patients themselves and one assessing hydroxychloroquine treatment in people who had been exposed to Covid-19 but weren’t yet ill.
The continuing spread of SARS-CoV-2 remains a Public Health Emergency of International Concern. What physicians need to know about transmission, diagnosis, and treatment of Covid-19 is the subject of ongoing updates from infectious disease experts at the Journal.
Eric Rubin is the Editor-in-Chief of the Journal. Lindsey Baden is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal.
Featuring articles on deaths due to e-cigarette– or vaping-associated lung injury, apixaban for venous thromboembolism in cancer, the management of coronary disease in patients with advanced kidney disease, health-status outcomes in the ISCHEMIA-CKD trial, and ten weeks to crush the curve.
Additionally, renin–angiotensin–aldosterone system inhibitors in patients with Covid-19, and teasing the immune system to repair the heart; a review article on the care of patients with diabetic retinopathy; a case report of a man with high blood pressure, renal insufficiency, and hematuria; and Perspective articles on clinical and social risk adjustment, on prediction models, and on medical care during the pandemic.
Tension-type headaches can be either episodic or chronic. They are rarely disabling or associated with any significant autonomic phenomena, thus patients do not usually seek medical care and usually successfully self-treat. Unlike migraine, there is no significant nausea, no vomiting, and a lack of aggravation by routine physical activity.
In this podcast Mark Green, Professor of Neurology, Anesthesiology and Rehabilitation Medicine, Director of Headache and Pain Medicine, Icahn School of Medicine at Mount Sinai, New York, gives a clinical overview of the condition.
SCIENTISTS ARE working at an unprecedented pace to find a vaccine for SARS-CoV-2, the virus that causes covid-19. The stakes are high. Natasha Loder, The Economist’s health policy editor, explains how an effective vaccine might be developed.
Dr Trevor Drew of the Australian Centre for Disease Preparedness speaks to host Kenneth Cukier about two trials which have reached the animal-testing stage. Plus, once a vaccine is discovered, what can be done to make sure it is distributed fairly? Dr Seth Berkely, chief executive of GAVI, the vaccine alliance, explains the importance of global cooperation. Runtime: 26 min
On this week’s show, Staff Writer Robert Service talks with host Sarah Crespi about a new National Academy of Sciences report that suggests the novel coronavirus can go airborne, the evidence for this idea, and what this means for the mask-wearing debate.
Also this week, Staff Writer Jennifer Couzin-Frankel joins Sarah to talk about a burgeoning understanding of the biological roots of anorexia nervosa—an eating disorder that affects about 1% of people in the United States. From genetic links to brain scans, scientists are finding a lot more biology behind what was once thought of as a culturally driven disorder.
Conclusion: The study was inconclusive with respect to potential differences in progression of individual radiographic features after surgical and non-surgical treatment for degenerative meniscal tear. Further, we found no strong evidence in support of differences in development of incident radiographic knee osteoarthritis or patient-reported outcomes between exercise therapy and arthroscopic partial meniscectomy.
Objective: To evaluate progression of individual radiographic features 5 years following exercise therapy or arthroscopic partial meniscectomy as treatment for degenerative meniscal tear.
Design: Randomized controlled trial including 140 adults, aged 35-60 years, with a magnetic resonance image verified degenerative meniscal tear, and 96% without definite radiographic knee osteoarthritis. Participants were randomized to either 12-weeks of supervised exercise therapy or arthroscopic partial meniscectomy. The primary outcome was between-group difference in progression of tibiofemoral joint space narrowing and marginal osteophytes at 5 years, assessed semi-quantitatively by the OARSI atlas. Secondary outcomes included incidence of radiographic knee osteoarthritis and symptomatic knee osteoarthritis, medial tibiofemoral fixed joint space width (quantitatively assessed), and patient-reported outcome measures. Statistical analyses were performed using a full analysis set. Per protocol and as treated analysis were also performed.
Results: The risk ratios (95% CI) for progression of semi-quantitatively assessed joint space narrowing and medial and lateral osteophytes for the surgery group were 0.89 (0.55-1.44), 1.15 (0.79-1.68) and 0.77 (0.42-1.42), respectively, compared to the exercise therapy group. In secondary outcomes (full-set analysis) no statistically significant between-group differences were found.
Scientists around the world are racing to develop a vaccine for COVID-19. But experts have said it could take a year to 18 months for one to hit the market. The process for testing and approving a vaccine is long and complicated.
That can be frustrating when the coronavirus is taking more and more lives every day. But cutting corners to push a vaccine through faster can lead to devastating consequences. We know that, because it’s happened before.